Evidence map›Paper›PMID 17018597›Full record

ArticleCancer research2006

High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.

Yuri Kotliarov, Mary Ellen Steed, Neil Christopher, Jennifer Walling, Qin Su, Angela Center, John Heiss, Mark Rosenblum, Tom Mikkelsen, Jean C Zenklusen and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Cancer research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Obstacles to Brain Tumor Therapy: Key ABC Transporters.International journal of molecular sciences · 2017
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Module cover - a new approach to genotype-phenotype studies.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2013
    Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors.

Yuri KotliarovNeuro-Oncology Branch, National Cancer Institute, Bethesda, MD 20892-4254, USA.
Mary Ellen Steed
Neil Christopher
Jennifer Walling
Qin Su
Angela Center
John Heiss
Mark Rosenblum
Tom Mikkelsen
Jean C Zenklusen
Howard A Fine

Funding

Molecular Pathogenesis of NeoplasiaZIANS003052 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HEISS, JOHN · 2009 to 2025
$20.7M
Treatment of Central Nervous System Tumors in Children/AZ01SC010100 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FINE, HOWARD A · 2000 to 2008
$4.5M
A MULTI-USE GLIOMA BIOREPOSITORYR24CA095809 · NCI · HENRY FORD HEALTH SYSTEM · PI MIKKELSEN, TOM · 2002 to 2006
$886k
Intramural NIH HHS ZIA NS003052NCI NIH HHS CA095809NCI NIH HHS R24 CA095809
6 · The paper itself

Abstract

Primary brain tumors are the fourth leading cause of cancer mortality in adults under the age of 54 years and the leading cause of cancer mortality in children in the United States. Therapy for the most common type of primary brain tumors, gliomas, remains suboptimal. The development of new and more effective treatments will likely require a better understanding of the biology of these tumors. Here, we show that use of the high-density 100K single-nucleotide polymorphism arrays in a large number of primary tumor samples allows for a much higher resolution survey of the glioma genome than has been previously reported in any tumor type. We not only confirmed alterations in genomic areas previously reported to be affected in gliomas, but we also refined the location of those sites and uncovered multiple, previously unknown regions that are affected by copy number alterations (amplifications, homozygous and heterozygous deletions) as well as allelic imbalances (loss of heterozygosity/gene conversions). The wealth of genomic data produced may allow for the development of a more rational molecular classification of gliomas and serve as an important starting point in the search for new molecular therapeutic targets.

Indexed as

AllelesGene DosageGenomic LibraryOligonucleotide Array Sequence AnalysisBrain NeoplasmsDNA, NeoplasmErbB ReceptorsGene AmplificationGliomaHumansLoss of HeterozygosityPolymerase Chain ReactionRNA, MessengerRNA, NeoplasmUnited StatesDNA, NeoplasmEGFR protein, humanErbB ReceptorsRNA, MessengerRNA, Neoplasm

Identifiers

PMID17018597
PMCPMC4316202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.